{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:11:29Z","timestamp":1789726289920,"version":"4.0.1"},"reference-count":35,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T00:00:00Z","timestamp":1598486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","award":["Inhaled Antibiotics in Bronchiectasis and Cystic F"],"award-info":[{"award-number":["Inhaled Antibiotics in Bronchiectasis and Cystic F"]}],"id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2020,7,18]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>\n                    The study aimed to determine the efficacy of a safe and well-tolerated dose and regimen of tobramycin inhalation powder (TIP) on\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    sputum density in patients with bronchiectasis.\n                  <\/jats:p>\n                  <jats:p>\n                    This is a phase II, double-blind, randomised study in bronchiectasis patients aged \u226518\u2005years with chronic\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    infection. Patients were randomised 1:1:1 to either cohort A: three capsules of TIP once daily (84\u2005mg); cohort B: five capsules once daily (140\u2005mg) or cohort C: four capsules twice daily (224\u2005mg). Within each cohort, patients were further randomised 2:2:1 either to TIP continuously, TIP cyclically (alternating 28\u2005days of TIP and placebo) or placebo for 16\u2005weeks, respectively and were followed up for 8\u2005weeks.\n                  <\/jats:p>\n                  <jats:p>\n                    Overall, 107 patients were randomised to cohorts A (n=34), B (n=36) and C (n=37). All three TIP doses significantly reduced the\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    sputum density from baseline to day 29\n                    <jats:italic>versus<\/jats:italic>\n                    placebo in a dose-dependent manner (p\u22640.0001, each). A smaller proportion of patients in the continuous-TIP (34.1%) and cyclical-TIP (35.7%) groups experienced pulmonary exacerbations\n                    <jats:italic>versus<\/jats:italic>\n                    placebo (47.6%) and also required fewer anti-pseudomonal antibiotics (38.6% on continuous TIP and 42.9% on cyclical TIP)\n                    <jats:italic>versus<\/jats:italic>\n                    placebo (57.1%) although not statistically significant. Pulmonary exacerbation of bronchiectasis was the most frequent (37.4%) adverse event. Overall, TIP was well tolerated, however, 23.4% of the patients discontinued the study drug due to adverse events.\n                  <\/jats:p>\n                  <jats:p>\n                    Continuous- and cyclical-TIP regimens with all three doses were safe and effective in reducing the\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    sputum density in patients with bronchiectasis and chronic\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    infection.\n                  <\/jats:p>","DOI":"10.1183\/13993003.01451-2020","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T13:20:41Z","timestamp":1598534441000},"page":"2001451","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy and safety of TOBI Podhaler in\n                    <i>Pseudomonas aeruginosa-<\/i>\n                    infected bronchiectasis patients: iBEST study"],"prefix":"10.1183","volume":"57","author":[{"given":"Michael R.","family":"Loebinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Polverino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm A.W.M.","family":"Tiddens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tunney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-4968","authenticated-orcid":false,"given":"Felix C.","family":"Ringshausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam T.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashidkhan","family":"Pathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhild","family":"Angyalosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles S.","family":"Haworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"2024102101594938000_57.1.2001451.1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12890-018-0629-1","article-title":"Bronchiectasis: an emerging global epidemic","volume":"18","author":"Chotirmall","year":"2018","journal-title":"BMC Pulm Med"},{"key":"2024102101594938000_57.1.2001451.2","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/1479972317709649","article-title":"Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013","volume":"14","author":"Weycker","year":"2017","journal-title":"Chron Respir Dis"},{"key":"2024102101594938000_57.1.2001451.3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01033-2015"},{"key":"2024102101594938000_57.1.2001451.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00629-2017"},{"key":"2024102101594938000_57.1.2001451.5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.chest.2018.02.024","article-title":"Bronchiectasis and chronic airway disease: it is not just about asthma and COPD","volume":"154","author":"Martinez-Garcia","year":"2018","journal-title":"Chest"},{"key":"2024102101594938000_57.1.2001451.6","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1183\/20734735.007516","article-title":"Global impact of bronchiectasis and cystic fibrosis","volume":"12","author":"Redondo","year":"2016","journal-title":"Breathe (Sheff)"},{"key":"2024102101594938000_57.1.2001451.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02033-2018"},{"key":"2024102101594938000_57.1.2001451.8","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1631"},{"key":"2024102101594938000_57.1.2001451.9","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.4.7697234"},{"key":"2024102101594938000_57.1.2001451.10","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201506-333OC"},{"key":"2024102101594938000_57.1.2001451.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2017"},{"key":"2024102101594938000_57.1.2001451.12","doi-asserted-by":"crossref","first-page":"e000348","DOI":"10.1136\/bmjresp-2018-000348","article-title":"British Thoracic Society guideline for bronchiectasis in adults","volume":"5","author":"Hill","year":"2019","journal-title":"BMJ Open Respir Res"},{"key":"2024102101594938000_57.1.2001451.13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-2600(19)30185-7","article-title":"The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis","volume":"7","author":"Laska","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102101594938000_57.1.2001451.14","first-page":"CD012733","article-title":"Continuous versus intermittent antibiotics for non-cystic fibrosis bronchiectasis (Protocol)","volume":"7","author":"Donovan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2024102101594938000_57.1.2001451.15","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02052-2017"},{"key":"2024102101594938000_57.1.2001451.16","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2147\/PPA.S134759","article-title":"Adherence to tobramycin inhaled powder vs inhaled solution in patients with cystic fibrosis: analysis of US insurance claims data","volume":"11","author":"Hamed","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"2024102101594938000_57.1.2001451.17","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.2.9910086"},{"key":"2024102101594938000_57.1.2001451.18","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E099"},{"key":"2024102101594938000_57.1.2001451.19","doi-asserted-by":"publisher","DOI":"10.1378\/chest.127.4.1420"},{"key":"2024102101594938000_57.1.2001451.20","doi-asserted-by":"crossref","first-page":"101834","DOI":"10.1016\/j.pupt.2019.101834","article-title":"Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: design of a dose-finding study (iBEST-1)","volume":"58","author":"Loebinger","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"2024102101594938000_57.1.2001451.21","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-205918"},{"key":"2024102101594938000_57.1.2001451.22","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.21356"},{"key":"2024102101594938000_57.1.2001451.23","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.805122"},{"key":"2024102101594938000_57.1.2001451.24","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-203207"},{"key":"2024102101594938000_57.1.2001451.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0954-6111(99)90090-2"},{"key":"2024102101594938000_57.1.2001451.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.5.1503"},{"key":"2024102101594938000_57.1.2001451.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199306173282403"},{"key":"2024102101594938000_57.1.2001451.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901073400104"},{"key":"2024102101594938000_57.1.2001451.29","doi-asserted-by":"publisher","DOI":"10.1378\/chest.121.1.55"},{"key":"2024102101594938000_57.1.2001451.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201005-0756OC"},{"key":"2024102101594938000_57.1.2001451.31","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00119114"},{"key":"2024102101594938000_57.1.2001451.32","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jcrc.2013.04.008","article-title":"Previous antibiotic exposure and evolution of antibiotic resistance in mechanically ventilated patients with nosocomial infections","volume":"28","author":"Hui","year":"2013","journal-title":"J Crit Care"},{"key":"2024102101594938000_57.1.2001451.33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1164\/rccm.201809-1651OC","article-title":"Airway bacterial load and inhaled antibiotic response in bronchiectasis","volume":"200","author":"Sibila","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102101594938000_57.1.2001451.34","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02053-2017"},{"key":"2024102101594938000_57.1.2001451.35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S2213-2600(18)30427-2","article-title":"Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials","volume":"7","author":"Haworth","year":"2019","journal-title":"Lancet Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01451-2020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:36:55Z","timestamp":1740364615000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01451-2020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,5]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1183\/13993003.01451-2020"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01451-2020","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,27]]}}}